Balloon Kyphoplasty Clinical Evidence
Mortality Rates Following VCF
You just clicked a link to go to another website. If you continue, you will leave this site and go to a site run by someone else.
It is possible that some of the products on the other site are not approved in your country.
Content on this site is intended for healthcare professionals in countries with applicable health authority product registrations. The content may not be approved for use in your specific region or country. Please review applicable product labeling for your country for indications and instructions prior to use. If not approved, please exit this site.
Click “Continue” to close this window and view the site’s content.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
Medtronic, Inc. (“Medtronic”) offers RemoteView, which permits a user (“Programmer User”) of the Medtronic CareLink® 2090 Programmer (“Programmer”) to allow the viewing of information presently displayed on the Programmer screen with one or more individuals in remote locations anywhere in the world (“Remote Viewer”), including remote health care professionals or Medtronic representatives.
Limited License Grant. You are hereby granted a nonexclusive, nontransferable, terminable, nonassignable, nonsublicensable, limited license to install and use a copy of the Licensed Software solely for authorized and legitimate purposes. You may not otherwise copy, use, modify, reverse engineer, decompile, disassemble, create derivative works based on, or integrate with other systems or programs the Licensed Software without the prior written consent of Medtronic. You shall have sole responsibility for any fees or charges, including service or data charges, incurred by you in connection with your use of the Licensed Software. You shall not remove any proprietary or other legend or restrictive notice contained or included in the Licensed Software or other documentation associated with such Licensed Software. You agree to maintain any and all copyright, trademark, and other notices on the Licensed Software and any associated documentation.
Licensed Software Functionality and Data Use, Collection, Viewing, and Transfer.
“Active Remote Viewer” as referred to herein shall mean a Remote Viewer that has installed the Licensed Software and has at the relevant point in time an active network connection to a Medtronic server via the Licensed Software.
By installing or using the Licensed Software or clicking any acceptance button in connection with this Agreement, you acknowledge, understand, agree to, and consent to all of the following, including when you are an Active Remoter User:
) Registration. To obtain access to the Licensed Software, you must register at the Medtronic RemoteView website and establish a user name and password. All information that you provide in connection with such registration must be complete, accurate, and truthful. The user name and password are personal to you and must not be shared with anyone else. You will also not attempt, directly or indirectly, to disable, bypass, or defeat any password protection associated with the Licensed Software. Medtronic reserves the right to deny or disable any user name or password or request for any user name or password.
) Your Personal Information. Medtronic will collect information in connection with your registration and installation and use of the Licensed Software, including your first and last name, your email address, a selected security question(s) and your corresponding answer(s), your address, and your telephone number. You agree that Medtronic may store this personal information about you on a Medtronic server, including a server located in the United States of America.
) Session Key. To view the information on the Programmer, the Remote Viewer must generate a Session Key that must be shared with and entered by the Programmer User. “Session Key” as used herein means a unique token active for a limited period of time generated by the Remote Viewer. You agree not to share this Session Key with anyone other than the Programmer User who has initiated the specific session.
) Logging of Session Activity. Each time you log in to the Licensed Software, Medtronic will collect information about your activity, including in an aggregated log or database, regarding you and your session, including your name, username, computer name, IP address, operating system details, and session details (including transferring and sharing activity, start and end times, view only or control activity, and any chat messages between or among any Active Remote Viewers. You agree that Medtronic may store any personal information about you on a Medtronic server, including a server located in the United States of America.
) Active Remote Users. When you are an Active Remote Viewer: (1) you will be able to view the name and/or user name of any other Active Remote Viewer who is logged into the same Medtronic server; and (2) any other Active Remote Viewer who is actively logged into the same Medtronic server will be able to view your name and/or user name. The Licensed Software also permits one Active Remote Viewer to share the information being viewed to any other Active Remote Viewer. You must not share any information from the Medtronic programmer, including with any other Active Remote Viewer, absent the express permission from the Programmer User that is allowing you to view the information.
) Availability. Medtronic has limitations on the number of users that can concurrently log in to the Licensed Software at any given time. Thus, installation of or accessing the Licensed Software does not guarantee that it will be available to you for use at any time.
Permissions. By installing and using the Licensed Software, you represent that you have permission to do so from any associated clinic, hospital, or medical practice and that your use of the Licensed Software complies with any policies or requirements of such associated clinic, hospital, or medical practice. You are also responsible for confirming that the Programmer User has obtained any necessary patient consent before allowing you to view any patient information via the Licensed Software.
Your Acknowledgements. You acknowledge that the Licensed Software is not the exclusive method of viewing information from the Programmer and that the Licensed Software is not the exclusive method by which to obtain a patient’s implanted cardiac device data, including any data on the Programmer. You also acknowledge that the Licensed Software is not intended to be used as a life-sustaining or interventional tool during medical emergencies. You further acknowledge that Medtronic is not, and shall not be deemed to be, a provider of patient health care services by virtue of its provision of access to the Programmer screen information via the Licensed Software. You also acknowledge that information from the Licensed Software is not an electronic medical record and use of the Licensed Software does not in any way relieve you from using your best medical judgment to determine a proper course of treatment for patients.
Security/Privacy of Patient Data. Your use of the Licensed Software and any Session Keys shall be solely for legitimate and lawful purposes and not for any malicious purpose. You are solely responsible for and will use your best efforts in maintaining the confidentiality and security of any copies of the Licensed Software as well as any user name, password credentials, and any Session Keys that can be used in accessing the Licensed Software, a Medtronic server, or any information from a Programmer. You are solely responsible for and will use your best efforts in keeping any patient information you may receive or view in connection with the Licensed Software confidential and secure, and you will not attempt to capture or copy any patient information you view in any electronic or hard copy format without the express permission of the Programmer User. You will be responsible for any obligations or liabilities associated with any lost, stolen, or otherwise compromised patient information.
Reporting Issues and Feedback. You agree that you will report any issues or questions, technical or otherwise, regarding the Licensed Software promptly and directly to Medtronic. If you submit any comments or ideas to Medtronic, in the absence of a separate agreement regarding such submissions, you grant to Medtronic an unrestricted, royalty-free, irrevocable license to use, reproduce, display, perform, modify, transmit, and distribute such ideas in any medium and agree that Medtronic is free to use them for any purpose. In addition, Medtronic has no obligation to provide continued maintenance and support to you in connection with the Licensed Software. Any maintenance and support services provided by Medtronic shall be at Medtronic’s sole discretion.
Limitations of Liability.
THE LICENSED SOFTWARE IS PROVIDED TO YOU “AS IS,” AND MEDTRONIC EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES WITH RESPECT TO THE LICENSED SOFTWARE AND YOUR USE THEREOF, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, AND NONINFRINGEMENT. MEDTRONIC DOES NOT WARRANT THAT THE USE OF THE LICENSED SOFTWARE WILL BE UNINTERRUPTED OR ERROR-FREE.
Legal Compliance. You shall at all times use the Licensed Software in compliance with all applicable laws. You shall ensure that your installation and use of the Licensed Software complies with all applicable export and import laws, regulations, orders, and policies of the United States of America and any other applicable jurisdiction. You represent and warrant that (i) you are not located in a country that is subject to a U.S. Government embargo, or that has been designated by the U.S. Government as a “terrorist supporting” country, and (ii) you are not listed on any U.S. Government list of prohibited or restricted parties.
Term, Termination, Modifications, and Support. This Agreement shall be in effect from the date when you first install or use the Licensed Software. Medtronic may modify, amend, or terminate this Agreement at any time, including by providing notices or an updated version of this Agreement on a Medtronic website. Medtronic may modify, disable, or terminate your use or Medtronic’s support of the Licensed Software at any time, including by providing notices on a Medtronic website. All obligations which are ongoing in nature shall survive termination or expiration of this Agreement. At any time upon Medtronic’s request (including via a notice on a Medtronic website), you agree to promptly delete and terminate use of any and all copies of the Licensed Software. In addition, upon Medtronic’s request, you agree to provide written verification that you have destroyed all copies of the Licensed Software together with the manner, date, and time of such destruction.
NayaMed International Sárl Customers: Whether the RemoteView feature shall be used in connection with NayaMed customers or devices shall be solely within the discretion of NayaMed International Sárl. If the Licensed Software is used connection with NayaMed customers or devices, this Agreement shall be directly between you and NayaMed with respect to those uses.
Balloon Kyphoplasty Clinical Evidence
Mortality Rates Following VCF
This page contains a review of all recent, large (>1000 subjects), peer-reviewed clinical studies, with follow-up of at least 12 months, that have evaluated mortality rates following vertebral compression fracture in patients treated with balloon kyphoplasty, compared with other operative or nonoperative treatments.
When considered collectively, the studies provide evidence that balloon kyphoplasty patients tend to have improved survivorship, i.e., lower mortality risk, than those undergoing other vertebral augmentation or nonoperative treatments.
Based on an analysis of 68,752 vertebral compression fracture (VCF) patients from 2006 MEDPAR (Medicare) data, Chen et al. (2013) found improved adjusted survivorship by 15% for vertebroplasty (VP) and 32% for balloon kyphoplasty (BKP) patients compared to non-operated patients at three years follow-up. Edidin and coworkers’ 2011 study of 858,978 VCF patients, including 119,253 BKP patients and 63,693 VP patients, in the 100% U.S. Medicare data set (2005–2008) demonstrated that the relative risk of mortality for BKP patients was 44% and 23% lower than that for nonoperated and VP patients, respectively, at four years follow-up. Lange et al. (2014) also reported that vertebral augmentation patients had significantly less likelihood (43%) of mortality than nonoperated patients at 5 years, based on German claims data. Their data also suggested a possible five-year survival benefit for patients who received balloon kyphoplasty (66.7%) compared with patients who received vertebroplasty (58.7%)(p=0.68).
In contrast, an analysis of 126,392 VCF patients based on 2002-2006 outpatient and MEDPAR data by McCullough et al. (2013) found 17% lower risk of mortality at one year for the combined BKP and VP group compared to the non-operated group, but not after propensity score matching. Conversely, using a much larger dataset of approximately one million VCF patients, Edidin et al. (2015) found significantly elevated four-year propensity-adjusted risk of mortality for nonoperated patients by 62% and 30% compared to BKP and VP patients, respectively. Furthermore, BKP patients were determined to have 17% less risk of mortality for BKP over VP patients (p<0.001).
According to Edidin et al. (2015), the contrasting findings from the McCullough 2013 study may be due to several differences in the study design. Most notably, McCullough’s subgroup analysis excluded a large proportion of augmentation patients who underwent augmentation within 30 days, in their attempts to control for any overall health differences between the treatment groups. But this likely excluded patients who underwent augmentation for emergent care and would have benefited the most from treatment. Thus, McCullough’s subgroup analysis would have likely reduced the relative difference in survival benefits for the augmentation subgroup compared with the non-operated group.
Ong et al (2017) reported results of analysis of over 2 million VCF patients in the Medicare population. In this analysis, the authors concluded that the five-year period following 2009 saw a steep reduction in vertebral augmentation volume and patients who were afflicted with VCFs and treated between 2010-2014 had significantly higher mortality risk than patients treated in the preceding 5-year period.
This publication adds to the growing portfolio of clinical information on patient mortality risk to help providers make an informed treatment decision on the use of vertebral augmentation for patients with vertebral compression fractures.
For questions about balloon kyphoplasty and the clinical studies presented here, contact our Office of Medical Affairs at 1-800-876-3133 ext. 6044 (toll free), or 1-901-399-2044 (direct), or by sending an email message to email@example.com.
Ong KL, Beall DP, Frohbergh M, Lau E, Hirsch JA.
Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty "sham" trials?
Osteoporos Int. 2017 Oct 24. doi: 10.1007/s00198-017-4281-z. PubMed PMID: 29063215.
Balloon kyphoplasty (BKP) and vertebroplasty (VP) are associated with lower mortality risks than non-surgical management (NSM) of vertebral compression fractures (VCF). VP versus sham trials published in 2009 sparked controversy over its effectiveness. Rates of VP and BKP have decreased since 2009. In this study, the authors hypothesized that lower BKP/VP usage would lead to a greater mortality risk for VCF patients.
This study aims to evaluate if the mortality and morbidity of VCF patients during 2010-2014 had been impacted by the diminished use of BKP and VP during this period compared with the 2005-2009 period of higher BKP and VP usage.
Total: 2,077,944 patients
The authors conducted an analysis of 100% Medicare claims data for 2005-2014. Patients were included in this study if they were 65 years of age or older, had a newly diagnosed VCF, and did not have a VCF in the previous 12 months. Patients were stratified into BKP, VP, and NSM cohorts.
Patients were excluded if they were enrolled in an HMO plan, were not enrolled in Parts A and B of Medicare, or had a fusion within 12 months of their VCF diagnosis (NSM cohort) or between their diagnosis and their BKP/VP procedure.
The primary and secondary endpoints included in this study were: mortality, morbidity, readmission, hospital length of day (LOS), and discharge status. Survival and morbidity were analyzed by the Kaplan-Meyer method and compared between patient cohorts treated with NSM, BKP, or VP using multivariate Cox regression with adjustment for propensity score and other factors. Propensity score was derived for the probability of undergoing BKP or VP using logistic regression conditional on age, gender, race, census region, socioeconomic status, comorbidities, type of fracture, diagnosis of osteoporosis, fracture location, site of service and physician specialty of initial VCF diagnosis, and year.
Based on the analysis of the 100% Medicare claims data for 2005-2014, the authors found that there was a 10% decline in vertebral augmentation (either BKP or VP) volume. Specifically, the vertebral augmentation volume rate was 14% in 2014 compared to 24% in 2009 (p<0.001). When comparing time periods, the propensity-adjusted mortality risk for VCF patients was 4% (95% CI: 3%-4%; p<0.001) greater in 2010-2014 than 2005-2009.
The overall 10-year mortality risk for VCF patients was 85.1%.
As shown below, the propensity-adjusted 10-year mortality risk analysis of the data from 2005-2014 by treatment cohort revealed that individuals treated with NSM had a significantly higher mortality risk than those treated with BKP and VP; and those treated with BKP had a significantly lower mortality risk than those treated with VP.
Comparison of propensity-adjusted 10-year mortality risk
At one year, outcomes with at least 10% greater risk for NSM than BKP patients were cardiac complications (19%; 95% CI: 17%-21%; p<0.001) and pneumonia (23%; 95% CI: 22%-24%; p<0.001).
Note: The cause of death is unknown in the dataset, but various morbidities and mortality with pneumonia diagnosed in the 90 days prior to death were used to provide some insight into the health status leading to expiration.
Length of Hospital Stay and Discharge Status:
While patients treated with NSM had a relatively shorter length of hospital stay (mean 5.2 days) compared to BKP (5.4 days) and VP (6.6 days; p-values < 0.001), NSM patients also had a relatively higher risk of discharge to a skilled nursing facility (48%) compared to BKP (31%) and VP (39.6%) (p-values <0.001). NSM also had the lowest relative rate of discharge to their home (33.7%) compared to BKP (56.9%) and VP (47%) (p-values <0.001).
This study was unable to determine the criteria for referrals to BKP and VP compared to NSM. Because the NSM cohort was discharged to nursing facilities at a significantly higher rate than BKP and VP cohorts, the present analysis could not accurately assess the LOS between the three cohorts.
Length of stay was slightly longer for hospitalized BKP, but BKP’s having a higher likelihood to be discharged to home appears to reflect a shifting of the NSM patients from inpatient facilities to other facilities and does not reflect recovery of patients.
Based on this analysis of Medicare claims data from over 2 million elderly patients, the authors concluded that the five-year period following 2009 saw a steep reduction in vertebral augmentation volume and patients who were afflicted with VCFs and treated between 2010-2014 had significantly higher mortality risk than patients treated in the preceding 5-year period.
Edidin AA, Ong KL, Lau E, Kurtz SM.
Morbidity and mortality after vertebral fractures: comparison of vertebral augmentation and non-operative management in the medicare population.
Spine (Phila Pa 1976). 2015 Aug 1;40(15):1228-41. doi: 10.1097. PubMed PMID: 26020845.
Edidin and colleagues sought to test the following hypotheses: (1) vertebral compression fracture patients in a balloon kyphoplasty cohort would experience no difference in mortality and morbidity as compared to patients in a conservatively managed ('nonoperated') cohort; (2) vertebral compression fracture patients in a vertebroplasty cohort would experience no difference in mortality and morbidity compared to patients in a conservatively managed cohort; and (3) vertebral compression fracture patients in a balloon kyphoplasty cohort would experience no difference in mortality and morbidity compared to patients in a vertebroplasty cohort
Total: 1,038,956 patients
Retrospective database review of Medicare claims for the 2005–2009 time period of vertebral compression fracture patients with up to 4 years of follow-up.
The prevalence of morbidities was evaluated based on the coding of corresponding ICD-13 9-CM diagnosis and procedure codes, as well as relevant CPT-4 codes for specific morbidities and subsequent treatment.
The mortality, morbidity, and subsequent treatment risks were estimated by the Kaplan-Meier method.
Differences in these outcomes were assessed by multivariate Cox regression, adjusting for comorbidities and other covariates. Subgroup analysis was performed for all patients with pathologic (or osteoporotic) vertebral compression fractures.
Propensity score matching analysis was performed to address selection bias through potential misspecification and account for potential uneven distribution of measured covariates.
In the non-matched cohorts, the unadjusted Kaplan-Meier risk of mortality at 4 years was 49.4%, 46.2%, and 41.8% for the nonoperated, vertebroplasty, and balloon kyphoplasty cohorts, respectively. The adjusted 4-year mortality risk for the nonoperated cohort was found to be 55.0% (95.0% Confidence Interval [CI], 53.0%-56.0%; P<0.001) and 25.0% (95.0% CI, 23.0%-26.0%; P<0.001) higher than the balloon kyphoplasty and vertebroplasty cohorts, respectively.
The balloon kyphoplasty cohort also had a 19.0% lower adjusted 4-year mortality risk than the vertebroplasty cohort (adjusted hazard ratio [AHR]=0.81, 95.0% CI, 0.70-0.82; P<0.001).
After propensity matching, the Kaplan-Meier risk of mortality at 4 years was still found to be greater for the nonoperated cohort with a greater adjusted 4-year mortality risk than those in the propensity matched balloon kyphoplasty (AHR=1.62, 95.0% CI, 1.601.64; P<0.001) and vertebroplasty (AHR=1.30, 95.0% CI, 1.28-1.33; P<0.001) cohorts.
The adjusted risk of mortality at 4 years continued to be lower by 17.0% (AHR=0.83, 95% CI, 0.81-0.85; P<0.001) for the propensity matched balloon kyphoplasty cohort over the vertebroplasty cohort. After propensity matching, patients in the nonoperated cohort had greater adjusted 4-year mortality risk (with any pneumonia diagnosis or with pneumonia as principal diagnosis in the prior 90 days) than those in the balloon kyphoplasty and vertebroplasty cohorts. The adjusted risk of mortality was also lower for the propensity matched balloon kyphoplasty cohort over the vertebroplasty cohort.
The mortality findings were generally similar for the subgroup of osteoporotic vertebral compression fracture patients before and after propensity matching. For example, after propensity matching, the nonoperated osteoporotic vertebral compression fracture cohort had a 70.0% higher adjusted 4-year mortality risk (AHR=1.70, 95.0% CI, 1.67-1.74; P<0.001) than the balloon kyphoplasty osteoporotic vertebral compression fracture cohort.
After propensity matching, the balloon kyphoplasty osteoporotic vertebral compression fracture cohort also had a 17.0% lower adjusted 4-year mortality risk (AHR=0.83, 95.0% CI, 0.80-0.87; P<0.001) than the vertebroplasty osteoporotic vertebral compression fracture cohort. These comparisons between the nonoperated and balloon kyphoplasty cohorts and between the balloon kyphoplasty and vertebroplasty cohorts were consistent for the 3 subgroups analyzed— the overall osteoporotic vertebral compression fracture patients, osteoporotic vertebral compression fracture patients who survived at least 1 year, and non-cancer osteoporotic vertebral compression fracture patients.
Edidin and colleagues were unable to support the null hypotheses that vertebral compression fracture patients in the balloon kyphoplasty, vertebroplasty, and nonoperated cohorts would experience no difference in mortality and morbidity. Instead, the 4-year results showed that vertebral compression fracture patients in the Medicare population who received kyphoplasty and vertebroplasty experienced lower mortality and morbidity than vertebral compression fracture patients who received conservative management, even after using propensity matching analysis to account for potential treatment selection bias because treatment was not randomly assigned.
Edidin and colleagues also found that vertebral compression fracture patients in the balloon kyphoplasty cohort also experienced an additional 4-year survival benefit with fewer morbidities overall than the vertebroplasty cohort. These survival benefits for balloon kyphoplasty over vertebroplasty were also evident for the subgroups of osteoporotic vertebral compression fracture patients, including those who survived at least 1 year and those with no cancer diagnosis.
The reasons underlying these apparent differences in patient outcomes among the treated and untreated cohorts and the causality cannot easily be addressed using the Medicare data alone. Despite this, Edidin and colleagues found higher 4-year mortality risk with pneumonia diagnosed in the prior 90 days, as well as greater risk of pneumonia, which provides some insight into possible causes of death.
Lange A, Kasperk C, Alvares L, Sauermann S, Braun S.
Survival and cost comparison of kyphoplasty and percutaneous vertebroplasty using German claims data.
Spine (Phila Pa 1976). 2014 Feb 15;39(4): 318-26. doi: 10.1097/ BRS.00000000000 00135. PubMed PMID: 24299715.
Examine the overall survival and treatment costs from a third-party-payer perspective for patients with osteoporotic vertebral compression fractures treated by vertebral augmentation or conservative treatment in Germany
Total: 3,607 patients
Observational study with a follow-up time of up to 5 years
Claims data for 2005 to 2010 from a major health insurance fund were used.
Mortality risk differences between the operated (balloon kyphoplasty, percutaneous vertebroplasty) and nonoperated cohorts were assessed by using Cox regression.
Operated patient cohort was established by propensity score matching and adjusting for covariates.
For the matched operated patients with osteoporotic vertebral compression fractures, survival was estimated by using Kaplan-Meier method.
The operated cohort was 43.0% less likely to die than the nonoperated cohort in the 5-year study period (hazard ratio=0.57; P<0.001).
Patients who received balloon kyphoplasty had higher 60-month adjusted survival rate (66.7%) than those who received percutaneous vertebroplasty (58.7%)(P=0.68).
Cumulative 4-year mean overall costs after first diagnosis were lower for the balloon kyphoplasty patients (percutaneous vertebroplasty: €42,510 versus balloon kyphoplasty: €39,014).
Initial upfront higher costs driven by surgical treatment for patients who received balloon kyphoplasty are offset by considerable pharmacy costs in patients who received percutaneous vertebroplasty.
There were differences between the values of painkiller consumption (percutaneous vertebroplasty: €3321 versus balloon kyphoplasty: €2224).
Results suggest a higher overall survival rate for operated than nonoperated patients with osteoporotic vertebral compression fractures and indicate a potential survival benefit for patients who received balloon kyphoplasty compared with patients who received percutaneous vertebroplasty. The reasons merit further investigation.
Total costs were lower after 4 years for patients who received balloon kyphoplasty versus percutaneous vertebroplasty due to less consumption of pharmaceuticals
Chen AT, Cohen DB, Skolasky RL.
Impact of nonoperative treatment, vertebroplasty, and kyphoplasty on survival and morbidity after vertebral compression fracture in the medicare population. J Bone Joint Surg Am. 2013 Oct 2;95(19):1729-36. doi: 10.2106/JBJS.K.01649. PubMed PMID: 24088964.
Compare the survival rates, complications, lengths of hospital stay, hospital charges, discharge locations, readmissions, and repeat procedures for Medicare patients with new vertebral compression fractures that had been acutely treated with vertebroplasty kyphoplasty, or nonoperative modalities
Total: 68,752 patients
Retrospective database review with total follow-up of 129,783 person-years
The primary parameter of interest was survival at 6 months, 1 year, 2 years, and 3 years.
Secondary parameters of interest were complications, lengths of hospital stay, hospital charges, discharge locations, thirty-day readmission rates, and repeat procedures. Complications during the index hospitalization and at six months included mortality, pulmonary embolism, deep-vein thrombosis, pneumonia, infection, decubitus ulcer, and neurologic compromise.
The estimated three-year survival rates were 42.3%, 49.7%, and 59.9% for the nonoperative treatment, vertebroplasty, and kyphoplasty cohorts, respectively.
The adjusted risk of death was 20.0% lower for the kyphoplasty cohort than for the vertebroplasty cohort (hazard ratio=0.80, 95% confidence interval, 0.77 to 0.84).
Patients who were managed nonoperatively were hospitalized longer (average, 7.38 days) than those who were managed operatively (vertebroplasty average, 5.73 days; kyphoplasty average, 3.74 days). Patients who were managed with kyphoplasty had much higher odds of being routinely discharged to home than those who were managed nonoperatively (59.9% compared with 24.3%, respectively; P<0.001).
Thirty-day readmission rates were high for all 3 cohorts, but patients in the nonoperative cohort were much more likely to return (rate of readmission, 61.9% for the nonoperative cohort, 52.4% for the vertebroplasty cohort, and 35.2% for the kyphoplasty cohort; P<0.001).
With regard to specific morbidities and subsequent treatment, Patients in the kyphoplasty cohort were the least likely to have had pneumonia and decubitus ulcers during the index hospitalization and at 6 months postoperatively; however, kyphoplasty was more likely to result in a subsequent augmentation procedure than was vertebroplasty (9.41% compared with 7.89%; P<0.001).
Vertebral augmentation procedures appear to be associated with longer patient survival than nonoperative treatment does.
Kyphoplasty tends to have a more striking association with survival than vertebroplasty does, but it is costly and may have a higher rate of subsequent vertebral compression fracture.
The results of this study suggest that the beneficial impact of minimally invasive surgery for vertebral compression fractures reaches beyond the acute phase and is associated with improvements in terms of post-discharge survival and morbidity.
McCullough BJ, Comstock BA, Deyo RA, Kreuter W, Jarvik JG.
Major medical outcomes with spinal augmentation vs conservative therapy. JAMA Intern Med. 2013 Sep 9;173(16):1514-21. doi: 10.1001/jamainternmed.2013.8725. PubMed PMID: 23836009 ; PubMed Central PMCID: PMC4023124.
Compare major medical outcomes following treatment of osteoporotic vertebral fractures with spinal augmentation or conservative therapy. Additionally, evaluate the role of selection bias using preoperative outcomes and propensity score analysis.
Total: 126,392 patients
Retrospective cohort analysis of Medicare claims for the 2002 to 2006 period. Thirty-day and 1-year outcomes in patients with newly diagnosed vertebral fractures treated with spinal augmentation or conservative therapy were compared
The main outcomes and measures included mortality, major complications, and health care usage.
With regard to hospital usage, McCullough and colleagues recorded general hospital admissions, intensive care unit (ICU) admissions, and discharges to a skilled nursing facility (SNF) during the year following vertebral fracture; however, they did not include hospital admissions during which spinal augmentation was performed.
Outcomes were compared using traditional multivariate analyses adjusted for patient demographics and comorbid conditions. Propensity score matching also was utilized to select 9,017 pairs from the initial groups to compare the same outcomes.
Mortality was significantly lower in the augmented cohort than among controls (5.2% versus 6.7% at 1 year; hazard ratio [HR]=0.83; 95.0% Confidence Interval [CI], 0.75-0.92); however, patients in the augmented group who had not yet undergone augmentation (preoperative subgroup) had lower rates of medical complications 30 days post fracture than did controls (6.5% versus 9.5%; odds ratio [OR]=0.66; 95% CI, 0.57-0.78), suggesting that the augmented group was less medically ill.
After propensity score matching to better account for selection bias, 1-year mortality was not significantly different between the cohorts. Furthermore, 1-year major medical complications were also similar between the groups, and the augmented group had higher rates of health care usage, including hospital and intensive care unit admissions and discharges to skilled nursing facilities.
McCullough and colleagues concluded that, after accounting for selection bias, spinal augmentation did not improve mortality or major medical outcomes and was associated with greater health care usage than conservative therapy, and that their results highlighted how analyses of claims-based data that do not adequately account for unrecognized confounding can arrive at misleading conclusions.
Edidin AA, Ong KL, Lau E, Kurtz SM.
Mortality risk for operated and nonoperated vertebral fracture patients in the medicare population. J Bone Miner Res. 2011 Jul;26(7):161726. doi: 10.1002/ jbmr.353. PubMed PMID: 21308780.
Evaluate the mortality risk for patients with vertebral compression fractures undergoing different treatment modalities. Specifically, Edidin and colleagues sought to test the following hypotheses: (1) The mortality risk for nonoperated (i.e., conservative treatment) vertebral compression fractures patients is greater than for those who undergo operative (i.e., kyphoplasty or vertebroplasty) treatment; and (2) the mortality risks for vertebral compression fractures patients who undergo either kyphoplasty or vertebroplasty are similar
Total: 858,978 patients
Retrospective database review of Medicare Claims for the 2005–2008 time period of vertebral compression fracture patients with up to 4 years of follow-up
The mortality rate associated with vertebral compression fracture was evaluated by determining the date of death from the annual Medicare denominator file.
Survival of a vertebral compression fracture patient was calculated from the index diagnosis date until death or end of follow-up on December 31, 2008.
Survival of vertebral compression fracture patients in the 100.0% U.S. Medicare data set (2005–2008) was estimated by the Kaplan-Meier method, and the differences in mortality rates at up to 4 years were assessed by Cox regression (adjusted for comorbidities) between operated and nonoperated patients and between kyphoplasty and vertebroplasty patients.
An instrumental variables analysis was used to evaluate mortality-rate difference between kyphoplasty and vertebroplasty patients.
At up to 4 years of follow-up, patients in the operated cohort had a higher adjusted survival rate of 60.8% compared with 50.0% for patients in the nonoperated cohort (P<0.001) and were 37% less likely to die (adjusted hazard ratio [HR]=0.63, P<.001).
The adjusted survival rates for vertebral compression fractures patients following vertebroplasty or kyphoplasty were 57.3% and 62.8%, respectively (P<0.001).
The relative risk of mortality for kyphoplasty patients was 23.0% lower than that for vertebroplasty patients (adjusted HR=0.77, P<.001).
Using physician preference as an instrument, the absolute difference in the adjusted survival rate at 3 years was 7.29% higher in patients receiving kyphoplasty than vertebroplasty (P<.001), compared with a crude absolute rate difference of 5.09%.
Edidin and colleagues were able to utilize the 100.0% Medicare data set to provide a comparison of mortality risks in an extremely large vertebral compression fracture patient cohort and, as such, concluded that:
All studies presented:
Kyphon™ Balloon Kyphoplasty is a minimally invasive procedure for the treatment of pathological fractures of the vertebral body due to osteoporosis, cancer or benign lesion. Cancer includes multiple myeloma and metastatic lesions, including those arising from breast or lung, or lymphoma. Benign lesions include hemangioma and giant cell tumor.
IMPORTANT SAFETY INFORMATION
The complication rate with Kyphon™ Balloon Kyphoplasty has been demonstrated to be low. There are risks associated with the procedure (e.g., cement extravasation), including serious complications, and through rare, some of which may be fatal.
Risks of acrylic bone cements include cement leakage, which may cause tissue damage, nerve or circulatory problems, and other serious adverse events, such as:
• Cardiac arrest • Cerebrovascular accident
• Myocardial infarction • Pulmonary embolism
• Cardiac embolism
For complete information regarding indications for use, contraindications, warnings, precautions, adverse events, and methods of use, please reference the devices' Instructions for Use included with the product.
Based on Clinical Literature Review as of October 26, 2017
Disclaimer: This page may include information about products that may not be available in your region or country. Please consult the approved indications for use. Content on specific Medtronic products is not intended for users in markets that do not have authorization for use.